A systematic review on the efficacy and safety of Infliximab in patients with psoriasis

References

• Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis:Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5):826-50; PMID:18423260; http://dx.doi.org/10.1016/j.jaad.2008.02.039.
   PubMed Web of Science ®Google Scholar
• Prinz JC. Psoriasis vulgaris–a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26(4):326-32; PMID:11422184; http://dx.doi.org/10.1046/j.1365-2230.2001.00831.x.
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182(9):5836-45; PMID:19380832; http://dx.doi.org/10.4049/jimmunol.0802999.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Matsuki T, Komine M, Asahina A, Horai R, Nakae S, Ishigame H, Kakuta S, Saijo S, Iwakura Y. TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/- mice. J Immunol 2010; 185(3):1887-93; PMID:20610641; http://dx.doi.org/10.4049/jimmunol.1001227.
   PubMed Web of Science ®Google Scholar
• Sato K, Takaishi M, Tokuoka S, Sano S. Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model. PLoS One 2014; 9(11):e112408; PMID:25384035; http://dx.doi.org/10.1371/journal.pone.0112408.
   PubMed Web of Science ®Google Scholar
• Yang L, You S, Kumar V, Zhang C, Cao Y. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. J Exp Clin Cancer Res 2012 May 1; 31:40; http://dx.doi.org/10.1186/1756-9966-31-40.
   PubMed Web of Science ®Google Scholar
• Flisiak I, Zaniewski P, Rogalska M, Myśliwiec H, Jaroszewicz J, Chodynicka B. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine 2010; 52(3):225-9; PMID:20980160; http://dx.doi.org/10.1016/j.cyto.2010.09.012.
   PubMed Web of Science ®Google Scholar
• Austin LM, 0zawa M, Kikuchi T, Walters IB, Krueger JG.The majority of epidermal in psoriatic patients. J Invest Dermatol 1999; 113 (5):752-759; PMID:10571730; http://dx.doi.org/10.1046/j.1523-1747.1999.00749.x.
   PubMed Web of Science ®Google Scholar
• Duan H, Kohda T. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001; 26 (2):119-24; http://dx.doi.org/10.1016/S0923-1811(00)00167-5.
   PubMed Web of Science ®Google Scholar
• Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trial. Br Med J 2001; 323(7 303):42-46; PMID:11440947; http://dx.doi.org/10.1136/bmj.323.7303.42.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(1):31.e1-15; PMID:17097378; http://dx.doi.org/10.1016/j.jaad.2006.07.017.
   PubMedGoogle Scholar
• Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59(1):40-9; PMID:20547039; http://dx.doi.org/10.1016/j.jdermsci.2010.04.014.
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011; 165(5):1109-17; PMID:21910713; http://dx.doi.org/10.1111/j.1365-2133.2011.10615.x.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, Oct 15-21; 366(9494):1367-74; http://dx.doi.org/10.1016/S0140-6736(05)67566-6.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005, May; 152(5):954-60; http://dx.doi.org/10.1111/j.1365-2133.2005.06510.x.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001, Jun 9; 357(9271):1842-7; http://dx.doi.org/10.1016/S0140-6736(00)04954-0.
   PubMed Web of Science ®Google Scholar
• Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, Wang BX, Zhang FR, Li CY, Liu XM, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) 2012; 125(11):1845-51; PMID:22884040.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66(4):498-505; PMID:17114188; http://dx.doi.org/10.1136/ard.2006.058339.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64(8):1150-7; PMID:15677701; http://dx.doi.org/10.1136/ard.2004.032268.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N; RESPOND investigators. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND research. Ann Rheum Dis 2012; 71(4):541-8; PMID:21994233; http://dx.doi.org/10.1136/ard.2011.152223.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4):1227-36; PMID:15818699; http://dx.doi.org/10.1002/art.20967.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62(7):965-9; PMID:20589696; http://dx.doi.org/10.1002/acr.20155.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled research. J Eur Acad Dermatol Venereol 2011; 25(12):1402-8; http://dx.doi.org/10.1111/j.1468-3083.2011.03984.x.
   PubMed Web of Science ®Google Scholar